

Supplementary Table 1. Articles and case reports reviewed.

Hakami S, Alharthi Y, Alanazi AMM. Refractory Pyoderma Gangrenosum: Stabilized on Colch and Tumor Necrosis Factor (TNF) Inhibitor. <i>Cureus</i> . 2022;14(10):e30419. Published 2022 Oct 18. doi:10.7759/cureus.30419
García Del Pozo-Martin de Hijas MC, Agudo-Mena JL, Gómez-Sánchez ME, Escario-Travesedo E. Recalcitrant Pyoderma Gangrenosum and Subcorneal Pus Dermatitis Successfully Treated With Ada. <i>Pyoderma gangrenoso y dermatosis pustulosa subcórnea refractarios tratados con éxito mediante Ada</i> . <i>Actas Dermosifiliogr (Engl Ed)</i> . 2020;111(10):887-889. doi:10.1016/j.ad.2019.02.028
Kleinfelder RE, Hin N, Cubelli S, Snyder A, Kerdel F, Glick B. Multiple Facial Lesions of Recalcitrant Pyoderma Gangrenosum Successfully Treated with Ada. <i>J Clin Aesthet Dermatol</i> . 2019;12(5):28-32.
McAllister BP, Williams ED, Yoo LJ, et al. Refractory Peri Pyoderma Gangrenosum Successfully Treated With Intravenous Immunoglobulin: A Case Report. <i>Am J Gastroenterol</i> . 2015;110(12):1739-1740. doi:10.1038/ajg.2015.344
Shaath TS, Om A, Wolfe CM, Cohen GF. Case Report: Triple Combination Therapy for Recalcitrant Perineal Pyoderma Gangrenosum. <i>J Drugs Dermatol</i> . 2019;18(3):307-310.
Hinterberger L, Müller CS, Vogt T, Pföhler C. Ada: a treatment option for pyoderma gangrenosum after failure of Sys standard therapies. <i>Dermatol Ther (Heidelb)</i> . 2012;2(1):6. doi:10.1007/s13555-012-0006-6
Fakhar F, Memon S, Deitz D, Abramowitz R, Alpert DR. Refractory postSurg pyoderma gangrenosum in a patient with Beckwith Wiedemann syndrome: response to multimodal therapy. <i>BMJ Case Rep</i> . 2013;2013:bcr2013201084. Published 2013 Oct 23. doi:10.1136/bcr-2013-201084
Teich N. Failure of sublesional Inflix injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease. <i>Tech Coloproctol</i> . 2014;18(10):965-966. doi:10.1007/s10151-014-1192-2
Hooton TA, Hanson JF, Olerud JE. Recalcitrant cutaneous pyoderma gangrenosum with pulmonary involvement resolved with treatment of underlying plasma cell dyscrasia. <i>JAAD Case Rep</i> . 2021;9:28-30. Published 2021 Jan 12. doi:10.1016/j.jcdr.2020.12.028
Goldberg ND, Vadlamudi A, Parrish N. Tx of refractory Crohn's disease and pyoderma gangrenosum with a combination regimen of rifaximin, gentamicin and metronidazole. <i>Case Rep Gastroenterol</i> . 2015;9(1):25-28. Published 2015 Jan 24. doi:10.1159/000369965
Teich N, Klugmann T. Rapid improvement of refractory pyoderma gangrenosum with Inflix gel in a patient with U colitis. <i>J Crohns Colitis</i> . 2014;8(1):85-86. doi:10.1016/j.crohns.2013.06.003
Lee JH, Chang IK, Lee HE, et al. Treatment of Recalcitrant Pyoderma Gangrenosum with U Colitis by Ada Injection. <i>Ann Dermatol</i> . 2017;29(2):260-262. doi:10.5021/ad.2017.29.2.260
Lee FG, Song E, Wallace SJ, et al. Non-Surg Management of Complex Refractory Pyoderma Gangrenosum With Negative Pressure Wound Therapy With Instillation. <i>Cureus</i> . 2021;13(10):e18951. Published 2021 Oct 21. doi:10.7759/cureus.18951
Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR. Tofa for the Tx of refractory pyoderma gangrenosum. <i>Clin Exp Dermatol</i> . 2021;46(6):1082-1085. doi:10.1111/ced.14683
Cinotti E, Labeille B, Perrot JL, Pallot-Prades B, Cambazard F. Certolizumab for the Tx of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis. <i>Clin Exp Dermatol</i> . 2014;39(6):750-751. doi:10.1111/ced.12393
Greb JE, Gottlieb AB, Goldminz AM. High-dose Uste for the treatment of severe, recalcitrant pyoderma gangrenosum. <i>Dermatol Ther</i> . 2016;29(6):482-483. doi:10.1111/dth.12387
Baier C, Barak O. Gus as a treatment option for recalcitrant pyoderma gangrenosum. <i>JAAD Case Rep</i> . 2020;8:43-46. Published 2020 Dec 14. doi:10.1016/j.jcdr.2020.12.005
O'Connor C, Gallagher C, Hollywood A, Paul L, O'Connell M. Ana for recalcitrant pyoderma gangrenosum. <i>Clin Exp Dermatol</i> . 2021;46(8):1558-1560. doi:10.1111/ced.14809
Sun NZ, Ro T, Jolly P, Sayed CJ. Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa. <i>J Clin Aesthet Dermatol</i> . 2017;10(9):36-38.
Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Ada therapy for recalcitrant pyoderma gangrenosum. <i>J Burns Wounds</i> . 2006;5:e8. Published 2006 Nov 20.
Isami Y, Kawase Y, Kondo A, et al. Pyoderma gangrenosum associated with U colitis: A recalcitrant case responded to Ada with granulocyte and monocyte adsorption apheresis. <i>J Dermatol</i> . 2020;47(5):e213-e215. doi:10.1111/1346-8138.15303
Cafardi J, Sami N. Intravenous immunoglobulin as salvage therapy in refractory pyoderma gangrenosum: report of a case and review of the literature. <i>Case Rep Dermatol</i> . 2014;6(3):239-244. Published 2014 Oct 23. doi:10.1159/000368824
Low ZM, Mar A. Treatment of severe recalcitrant pyoderma gangrenosum with Uste. <i>Australas J Dermatol</i> . 2018;59(2):131-134. doi:10.1111/ajd.12744
de Sousa Magalhães R, Moreira MJ, Rosa B, Cotter J. O2 for refractory pyoderma gangrenosum: a salvage Tx. <i>BMJ Case Rep</i> . 2021;14(2):e238638. Published 2021 Feb 18. doi:10.1136/bcr-2020-238638

Choi AW, Abuav R, Rabizadeh SM, Ansari R, Marsch AF. Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral Tofa. <i>JAAD Case Rep.</i> 2020;6(9):939-941. Published 2020 Jul 29. doi:10.1016/j.jdc.2020.07.035
Burgdorf B, Schlott S, Ivanov IH, Dissemond J. Successful Tx of a refractory pyoderma gangrenosum with risankizumab. <i>Int Wound J.</i> 2020;17(4):1086-1088. doi:10.1111/iwj.13359
Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with Uste. <i>J Am Acad Dermatol.</i> 2012;67(5):e237-e238. doi:10.1016/j.jaad.2012.04.045
Nieto D, Sendagorta E, Rueda JM, Herranz P. Successful treatment with Uste and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. <i>Clin Exp Dermatol.</i> 2019;44(1):116-119. doi:10.1111/ced.13679
Low ZM, Mar A. Treatment of severe recalcitrant pyoderma gangrenosum with Uste. <i>Australas J Dermatol.</i> 2018;59(2):131-134. doi:10.1111/ajd.12744
Low ZM, Mar A. Treatment of severe recalcitrant pyoderma gangrenosum with Uste. <i>Australas J Dermatol.</i> 2018;59(2):131-134. doi:10.1111/ajd.12744
Salvia G, Michelucci A, Granieri G, et al. An Integrated Sys and Local Wound Management in Recalcitrant Pyoderma Gangrenosum [published online ahead of print, 2023 Jan 3]. <i>Int J Low Extrem Wounds.</i> 2023;15347346221148818. doi:10.1177/15347346221148818
Sun NZ, Ro T, Jolly P, Sayed CJ. Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa. <i>J Clin Aesthet Dermatol.</i> 2017;10(9):36-38.
Toussi A, Le ST, Barton VR, et al. Successful Management of Anti-TNF-Induced Psoriasis Despite Continuation of Therapy in a Pyoderma Gangrenosum Patient. <i>J Drugs Dermatol.</i> 2020;19(2):199-201. doi:10.36849/JDD.2020.4662
Charles CA, Leon A, Banta MR, Kirsner RS. Etan for the Tx of refractory pyoderma gangrenosum: a brief series. <i>Int J Dermatol.</i> 2007;46(10):1095-1099. doi:10.1111/j.1365-4632.2007.03286.x
Buhalog B, Eastman K, McDonald R. Recalcitrant pyoderma gangrenosum treated with parenteral iron sucrose therapy. <i>JAAD Case Rep.</i> 2015;1(2):54-55. Published 2015 Feb 5. doi:10.1016/j.jdc.2014.12.003
Kolios AG, Maul JT, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. <i>Br J Dermatol.</i> 2015;173(5):1216-1223. doi:10.1111/bjd.14037
O'Connor C, Gallagher C, Hollywood A, Paul L, O'Connell M. Ana for recalcitrant pyoderma gangrenosum. <i>Clin Exp Dermatol.</i> 2021;46(8):1558-1560. doi:10.1111/ced.14809
Zeeli T, Padalon-Brauch G, Ellenbogen E, Gat A, Sarig O, Sprecher E. Pyoderma gangrenosum, acne and U colitis in a patient with a novel mutation in the PSTPIP1 gene. <i>Clin Exp Dermatol.</i> 2015;40(4):367-372. doi:10.1111/ced.12585
Lesmeister LM, Peitz J, von Kleist-Retzow JC, et al. Inflix is an appropriate second-line therapy in infants with steroid refractory pyoderma gangrenosum. <i>J Eur Acad Dermatol Venereol.</i> 2022;36(5):e376-e378. doi:10.1111/jdv.17921
Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with Inflix. <i>Br J Dermatol.</i> 2005;153(3):689-691. doi:10.1111/j.1365-2133.2005.06812.x
Singh M, Andrew SM, Lear JT. Inflix as a treatment for recalcitrant pyoderma gangrenosum. <i>Clin Exp Dermatol.</i> 2004;29(2):196-197. doi:10.1111/j.1365-2230.2004.01470.x
Campos-Muñoz L, Conde-Taboada A, Aleo E, Toledano E, López-Bran E. Refractory pyoderma gangrenosum treated with Inflix in an infant. <i>Clin Exp Dermatol.</i> 2014;39(3):336-339. doi:10.1111/ced.12297
Salehzadeh F, Mohammadikebar Y, Enteshary A, Ghanbarpour O, Mirzarahimi M. Inflix in Tx of idiopathic refractory childhood pyoderma gangrenosum (PG). <i>Bios.</i> 2019;13:97-99. Published 2019 May 27. doi:10.2147/BTT.S203753
Campos-Muñoz L, Conde-Taboada A, Aleo E, Toledano E, López-Bran E. Refractory pyoderma gangrenosum treated with Inflix in an infant. <i>Clin Exp Dermatol.</i> 2014;39(3):336-339. doi:10.1111/ced.12297
Baliu-Piqué C, Mascaró JM Jr. Multifocal and refractory pyoderma gangrenosum: Possible role of cocaine abuse. <i>Australas J Dermatol.</i> 2017;58(3):e83-e86. doi:10.1111/ajd.12498
Sousa M, Campos MA, Sousa AC, Lopes J, Rodrigues A, Carvalho J. Extensive Refractory Perineal Pyoderma Gangrenosum Treated with Inflix, Fecal Diversion, and Negative-Pressure Wound Therapy. <i>GE Port J Gastroenterol.</i> 2020;27(2):128-131. doi:10.1159/000502982
Sadati MS, Dastgheib L, Aflaki E. Recalcitrant cases of pyoderma gangrenosum, responding dramatically to Sys Tacro. <i>G Ital Dermatol Venereol.</i> 2017;152(3):308-310. doi:10.23736/S0392-0488.17.04876-3
Uthman I, El-Sayad J, Sharara A. Successful treatment of recalcitrant pyoderma gangrenosum with Inflix complicated by tuberculosis despite negative screening tests. <i>Clin Exp Dermatol.</i> 2005;30(3):294. doi:10.1111/j.1365-2230.2004.01716.x
Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR. Tofa for the Tx of refractory pyoderma gangrenosum. <i>Clin Exp Dermatol.</i> 2021;46(6):1082-1085. doi:10.1111/ced.14683
Tai YJ, Kelly R. Pyoderma gangrenosum complicated by herpes simplex virus infection. <i>Australas J Dermatol.</i> 2005;46(3):161-164. doi:10.1111/j.1440-0960.2005.00170.x

Paulsen E, Bygum A. Keratin Gel as an Adjuvant in the Treatment of Recalcitrant Pyoderma Gangrenosum Ulcers: A Case Report. <i>Acta Derm Venereol.</i> 2019;99(2):234-235. doi:10.2340/00015555-3081
Khurram Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD. Top Tacro (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases. <i>Colorectal Dis.</i> 2004;6(4):250-253. doi:10.1111/j.1463-1318.2004.00607.x
Coe J, Kudva S, Shams K. Matching the dose to the disease: Successful treatment of recalcitrant pyoderma gangrenosum using high-dose Secu. <i>Dermatol Ther.</i> 2022;35(9):e15669. doi:10.1111/dth.15669
Nunes G, Patita M, Fernandes V. Refractory Pyoderma Gangrenosum in a Patient With Crohn's Disease: Complete Response to Uste. <i>J Crohns Colitis.</i> 2019;13(6):812-813. doi:10.1093/ecco-jcc/jyy200
Laird ME, Tong LX, Lo Sicco KI, Kim RH, Meehan SA, Franks AG Jr. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. <i>JAAD Case Rep.</i> 2017;3(3):228-229. Published 2017 Apr 14. doi:10.1016/j.jdc.2017.02.019
Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with Thalido. <i>Mayo Clin Proc.</i> 2000;75(8):842-844. doi:10.4065/75.8.842
Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: treatment with Thalido. <i>J Am Acad Dermatol.</i> 1998;38(3):490-491. doi:10.1016/s0190-9622(98)70513-4
Sadati MS, Dastgheib L, Aflaki E. Recalcitrant cases of pyoderma gangrenosum, responding dramatically to Sys Tacro. <i>G Ital Dermatol Venereol.</i> 2017;152(3):308-310. doi:10.23736/S0392-0488.17.04876-3
Lyon CC, Kirby B, Griffiths CE. Recalcitrant pyoderma gangrenosum treated with Sys Tacro. <i>Br J Dermatol.</i> 1999;140(3):562-564. doi:10.1046/j.1365-2133.1999.02745.x
Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective Cortico-sparing agent for recalcitrant pyoderma gangrenosum. <i>J Am Acad Dermatol.</i> 1996;35(5 Pt 1):720-724. doi:10.1016/s0190-9622(96)90727-6
Abu-Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. <i>Transplant Proc.</i> 1991;23(6):3328-3329.
Satake M, Sakuraba H, Hiraga H, et al. Successful Tx with Tacro of refractory pyoderma gangrenosum with pouchitis after restorative proctocolectomy for U colitis. <i>Immunol Med.</i> 2018;41(3):142-146. doi:10.1080/25785826.2018.1531194
Weichert G, Sauder DN. Efficacy of Tacro (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum. <i>J Am Acad Dermatol.</i> 1998;39(4 Pt 1):648-650. doi:10.1016/s0190-9622(98)70020-9
Jolles S, Niclasse S, Benson E. Combination oral and Top Tacro in therapy-resistant pyoderma gangrenosum. <i>Br J Dermatol.</i> 1999;140(3):564-565. doi:10.1046/j.1365-2133.1999.02746.x
Kapetanovic I, Tanasilovic S, Lalosevic J, Zivanovic D. Refractory steroid-resistant pyoderma gangrenosum successfully treated with intravenous immunoglobulins. <i>Dermatol Ther.</i> 2020;33(6):e14322. doi:10.1111/dth.14322
de Zwaan SE, Iland HJ, Damian DL. Tx of refractory pyoderma gangrenosum with intravenous immunoglobulin. <i>Australas J Dermatol.</i> 2009;50(1):56-59. doi:10.1111/j.1440-0960.2008.00506.x
Hayashi H, Kuwabara C, Tarumi K, Makino E, Fujimoto W. Successful Tx with Inflix for refractory pyoderma gangrenosum associated with inflammatory bowel disease. <i>J Dermatol.</i> 2012;39(6):576-578. doi:10.1111/j.1346-8138.2011.01346.x
Zampeli VA, Lippert U, Nikolakis G, et al. Disseminated refractory pyoderma gangraenosum during an U colitis flare. Tx with Inflix. <i>J Dermatol Case Rep.</i> 2015;9(3):62-66. Published 2015 Sep 30. doi:10.3315/jdc.2015.1206
Gündüz K, Gülbaşaran F, Hasdemir PS, Temiz P, Inanır I. Successful Tx of severe refractory post-cesarean pyoderma gangrenosum with intravenous immunoglobulin. <i>Dermatol Ther.</i> 2020;33(6):e14121. doi:10.1111/dth.14121
Ueda M, Katoh M, Tanizaki H, Tanioka M, Matsumura Y, Miyachi Y. Refractory pyoderma gangrenosum associated with U colitis successfully treated with Inflix. <i>Dermatol Online J.</i> 2012;18(1):12. Published 2012 Jan 15.
Ibrahim I, Shereef H, Hashim A, Habbal H, Mahmood R, Mohamed MA. Winning the Battle after Three Years of Suffering: A Case of a Refractory Pyoderma Gangrenosum Tx Challenge. <i>Case Rep Rheumatol.</i> 2021;2021:8869914. Published 2021 Mar 13. doi:10.1155/2021/8869914
Jenne L, Sauter B, Thumann P, Hertl M, Schuler G. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with Inflix (chimeric antitumour necrosis factor antibody). <i>Br J Dermatol.</i> 2004;150(2):380-382. doi:10.1111/j.1365-2133.2003.05760.x
Hanafusa T, Azukizawa H, Umegaki N, Tani M, Yamaguchi Y, Katayama I. Clinical implications of leukocytapheresis using a centrifugal cell separator for steroid-resistant pyoderma gangrenosum associated with inflammatory bowel disease. <i>J Dermatol.</i> 2011;38(5):507-510. doi:10.1111/j.1346-8138.2010.01009.x
Okuma K, Mitsuishi K, Hasegawa T, Tsuchihashi H, Ogawa H, Ikeda S. A case report of steroid and ISpressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. <i>Ther Apher Dial.</i> 2007;11(5):387-390. doi:10.1111/j.1744-9987.2007.00498.x
Ferkolj I, Hocevar A, Golouh R, Dolenc Voljc M. Inflix for treatment of resistant pyoderma gangrenosum associated with Crohn's disease. <i>Acta Dermatovenerol Alp Pannonica Adriat.</i> 2006;15(4):173-177.

Jin SY, Chen M, Wang FY, Wang F. Applying Intravenous Immunoglobulin and Negative-Pressure Wound Therapy to Treat Refractory Pyoderma Gangrenosum: A Case Report. <i>Int J Low Extrem Wounds</i> . 2021;20(2):158-161. doi:10.1177/1534734620940459
Young KZ, Guan LL, Friedman BJ, Rambhatla PV. Recalcitrant vulvar pyoderma gangrenosum successfully treated with MMF mofetil. <i>Int J Womens Dermatol</i> . 2022;8(3):e061. Published 2022 Oct 21. doi:10.1097/JW9.000000000000061
Matis WL, Ellis CN, Griffiths CE, Lazarus GS. Treatment of pyoderma gangrenosum with Cyclo. <i>Arch Dermatol</i> . 1992;128(8):1060-1064.
Park HJ, Han BG, Kim YC, Cinn YW. Recalcitrant oral pyoderma gangrenosum in a child responsive to Cyclo. <i>J Dermatol</i> . 2003;30(8):612-616. doi:10.1111/j.1346-8138.2003.tb00444.x
Newell LM, Malkinson FD. Pyoderma gangrenosum. Response to Cyclophos therapy. <i>Arch Dermatol</i> . 1983;119(6):495-497. doi:10.1001/archderm.119.6.495
Fullerton SH, Abel EA, Getz K, el-Ramahi K. Cyclo treatment of severe recalcitrant pyoderma gangrenosum in a patient with Takayasu's arteritis. <i>Arch Dermatol</i> . 1991;127(11):1731-1732.
Kavanagh GM, Ross JS, Cronin E, Smith NP, Black MM. Recalcitrant pyoderma gangrenosum--two cases successfully treated with cyclosporin A. <i>Clin Exp Dermatol</i> . 1992;17(1):49-52. doi:10.1111/j.1365-2230.1992.tb02535.x
Soria C, Allegue F, Martin M, Ledo A. Treatment of pyoderma gangrenosum with cyclosporin A. <i>Clin Exp Dermatol</i> . 1991;16(5):392-394. doi:10.1111/j.1365-2230.1991.tb00409.x
Magid ML, Gold MH. Treatment of recalcitrant pyoderma gangrenosum with Cyclo. <i>J Am Acad Dermatol</i> . 1989;20(2 Pt 1):293-294. doi:10.1016/s0190-9622(89)80063-5
Huang X, Han K, Xue R, Li L, Zeng K, Liang L. Successful Tx with oral methylprednisolone and Cyclo for refractory pyoderma gangrenosum in children: Report of a case and review of the literature. <i>Clin Case Rep</i> . 2020;8(3):416-419. Published 2020 Jan 25. doi:10.1002/ccr3.2263
Kosari P, Feldman SR. Letter: Treatment-resistant pyoderma gangrenosum. <i>Dermatol Online J</i> . 2012;18(4):8. Published 2012 Apr 15.
Matis WL, Ellis CN, Griffiths CE, Lazarus GS. Treatment of pyoderma gangrenosum with Cyclo. <i>Arch Dermatol</i> . 1992;128(8):1060-1064.
Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective Cortico-sparing agent for recalcitrant pyoderma gangrenosum. <i>J Am Acad Dermatol</i> . 1996;35(5 Pt 1):720-724. doi:10.1016/s0190-9622(96)90727-11
Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with MMF mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. <i>J Eur Acad Dermatol Venereol</i> . 2000;14(3):187-190. doi:10.1046/j.1468-3083.2000.00019.x
Abu-Elmagd K, Jegasothy BV, Ackerman CD, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. <i>Transplant Proc</i> . 1991;23(6):3328-3329.
Kark EC, Davis BR, Pomeranz JR. Pyoderma gangrenosum treated with clofazimine. Report of three cases. <i>J Am Acad Dermatol</i> . 1981;4(2):152-159. doi:10.1016/s0190-9622(81)70018-5
Gopi SS, Evans AT, Raza A, Byrne DJ. Superficial granulomatous pyoderma gangrenosum of the penis: a case report. <i>ScientificWorldJournal</i> . 2007;7:2426-2429. Published 2007 May 5. doi:10.1100/tsw.2006.376
Koester G, Tarnower A, Levisohn D, Burgdorf W. B pyoderma gangrenosum. <i>J Am Acad Dermatol</i> . 1993;29(5 Pt 2):875-878. doi:10.1016/0190-9622(93)70261-q
Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. <i>Ther Apher Dial</i> . 2007;11(3):177-182. doi:10.1111/j.1744-9987.2007.00424.x
Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of MMF mofetil in refractory pyoderma gangrenosum. <i>Arch Dermatol</i> . 1998;134(12):1509-1511. doi:10.1001/archderm.134.12.1509
Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR. Tofa for the Tx of refractory pyoderma gangrenosum. <i>Clin Exp Dermatol</i> . 2021;46(6):1082-1085. doi:10.1111/ced.14683
Baglieri, F. and Scuderi, G. (2010), THERAPEUTIC HOTLINE: Inflix for treatment of resistant pyoderma gangrenosum associated with U colitis and psoriasis. A case report. <i>Dermatologic Therapy</i> , 23: 541-543. https://doi.org/10.1111/j.1529-8019.2010.01357.x
Kosari P, Feldman SR. Letter: Treatment-resistant pyoderma gangrenosum. <i>Dermatol Online J</i> . 2012;18(4):8. Published 2012 Apr 15.
Adams J, Habenicht D, Gibran Y. COVID-19 infection and treatment-resistant cocaine-induced pyoderma gangrenosum: A case report. <i>Ann Med Surg (Lond)</i> . 2022;78:103828. doi:10.1016/j.amsu.2022.103828
Mulholland O, Middleton D, Hunter H. Negative-pressure wound therapy as an adjunct to treating pyoderma gangrenosum. <i>J R Coll Physicians Edinb</i> . 2022;52(3):260-262. doi:10.1177/14782715221126768
Dozier L, Ceresnie M, Habashy J, Kerdel F. Improvement of refractory pyoderma gangrenosum with adjunctive maggot debridement therapy [published online ahead of print, 2022 Dec 5]. <i>Int J Dermatol</i> . 2022;10.1111/ijd.16531. doi:10.1111/ijd.16531

Levy D, Banta MR, Kirsner RS. Refractory pyoderma gangrenosum Peri ulcer and sinus tract treated with micronized cadaveric dermis. <i>J Am Acad Dermatol.</i> 2005;52(6):1104. doi:10.1016/j.jaad.2004.10.014
Alvarez-Lopez MA, Burón-Alvarez I, Villegas-Fernández C. Refractory pyoderma gangrenosum treated with platelet-rich plasma. <i>J Eur Acad Dermatol Venereol.</i> 2016;30(8):1423-1424. doi:10.1111/jdv.13265
Pearson WA, Prentice DA, Sinclair DL, Lim LY, Carville KJ. A novel Top therapy for resistant and early Peri pyoderma gangrenosum. <i>Int Wound J.</i> 2019;16(5):1136-1143. doi:10.1111/iwj.13164
Khurram Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD. Top Tacro (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases. <i>Colorectal Dis.</i> 2004;6(4):250-253. doi:10.1111/j.1463-1318.2004.00607.x
Hoetzenecker W, Guenova E, Mitev V, Schanz S, Ulmer A, Fierlbeck G. Treatment of pyoderma gangrenosum with Top factor XIII. <i>Eur J Dermatol.</i> 2013;23(5):653-657. doi:10.1684/ejd.2013.2147
Kark EC, Davis BR, Pomeranz JR. Pyoderma gangrenosum treated with clofazimine. Report of three cases. <i>J Am Acad Dermatol.</i> 1981;4(2):152-159. doi:10.1016/s0190-9622(81)70018-5
Pearson WA, Prentice DA, Sinclair DL, Lim LY, Carville KJ. A novel Top therapy for resistant and early Peri pyoderma gangrenosum. <i>Int Wound J.</i> 2019;16(5):1136-1143. doi:10.1111/iwj.13164
Kolios AG, Maul JT, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. <i>Br J Dermatol.</i> 2015;173(5):1216-1223. doi:10.1111/bjd.14037
John JM, Sinclair RD. Tildra for Tx of refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica: Killing two birds with one stone. <i>Australas J Dermatol.</i> 2020;61(2):170-171. doi:10.1111/ajd.13196
Leow LJ, Zubrzycki N. Recalcitrant U Pyoderma Gangrenosum of the Leg Responsive to Tildra: A Case Report. <i>Clin Cosmet Investig Dermatol.</i> 2022;15:1729-1736. Published 2022 Aug 23. doi:10.2147/CCID.S374534
Cosgarea I, Lovric Z, Körber A, Dissemond J. Successful Tx of refractory pyoderma gangrenosum with Uste only after excision of renal cell carcinoma. <i>Int Wound J.</i> 2016;13(5):1041-1042. doi:10.1111/iwj.12377
Vallerand IA, Hardin J. Uste for the treatment of recalcitrant pyoderma gangrenosum: A case report. <i>SAGE Open Med Case Rep.</i> 2019;7:2050313X19845206. Published 2019 May 2. doi:10.1177/2050313X19845206